ImCheck Therapeutics
FranceWho owns ImCheck Therapeutics?
ImCheck Therapeutics is a French Biotech company, now owned by Ipsen, which acquired it in 2025 from Boehringer Ingelheim Venture Fund, Wellington Partners and 2 other investors.
Hand-verified · updated 2026-09-30
Open JSON · CC-BY
Key facts
- ·Fully exited in 2025 to Ipsen.
- ·Average hold across 3 realized cycles: 6 years.
- ·4 distinct PE sponsors across ownership cycles.
Ownership history
4 ownership periods · co-invest detected
Boehringer Ingelheim Venture Fund sold ImCheck Therapeutics to Ipsen in 2025 after 8 years.
Wellington Partners sold ImCheck Therapeutics to Ipsen in 2025 after 6 years.
Earlybird Venture Capital sold ImCheck Therapeutics to Ipsen in 2025 after 3 years.
Gimv sold ImCheck Therapeutics to Ipsen in 2025.
More from Earlybird Health
Other portfolio companies in the same fund.
UK
Switzerland
USMore PE-backed in Biotech
Comparable biotech deals from other GPs.
Questions
Who owns ImCheck Therapeutics?
ImCheck Therapeutics is now owned by Ipsen, which acquired it in 2025 from Boehringer Ingelheim Venture Fund, Wellington Partners and 2 other investors.
When did Ipsen acquire ImCheck Therapeutics?
Ipsen acquired ImCheck Therapeutics in 2025, buying from Boehringer Ingelheim Venture Fund, Wellington Partners and 2 other investors.
Who did ImCheck Therapeutics sell to?
Boehringer Ingelheim Venture Fund, Wellington Partners and 2 other investors sold ImCheck Therapeutics to Ipsen in 2025 (Trade Sale).
Who has owned ImCheck Therapeutics over time?
ImCheck Therapeutics has been through 4 private-equity ownership periods: Boehringer Ingelheim Venture Fund · via Boehringer Ingelheim Venture Fund · 2017–2025 · sold to Ipsen · (Trade Sale); Wellington Partners · via Wellington Partners Life Sciences · 2019–2025 · sold to Ipsen · (Trade Sale); Earlybird Venture Capital · via Earlybird Health · 2022–2025 · sold to Ipsen · (Trade Sale); Gimv · sold to Ipsen · (Trade Sale).